FDA Expands Use of Liver Drug to Subset of Patients

The U.S. Food and Drug Administration has expanded the use of Gilead Sciences Inc's drug Harvoni (ledipasvir and sofosbuvir) to some hepatitis C patients in the advanced stage of cirrhosis, including those who have undergone liver transplant.